Cantor Fitzgerald raised the firm’s price target on Immunovant to $45 from $30 and keeps an Overweight rating on the shares following positive data for IMVT-1402 and ahead of readouts from Graves’ Disease and others. The price target increase is due to multiple expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Netflix downgraded, Applied Materials upgraded: Wall Street’s top analyst calls
- Immunovant upgraded to Buy from Neutral at UBS
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Insider Trading: Immunovant Stock (NASDAQ:IMVT) Gains on Director’s Huge Buy
- Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares